Huntington's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Huntington's Disease, including details on genetics, causes, symptoms, treatment.

Volume 3 (2007), Issue 4 (April)

1. The corridor task: striatal lesion effects and graft-mediated recovery in a model of Huntington's disease.
   Behav Brain Res, 179(2): 326-30. [Abstract] [Full-text]
2. Complex movement behaviour and progression of Huntington's disease.
   Neurosci Lett, 416(3): 272-4. [Abstract] [Full-text]
3. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease.
   J Neurosci, 27(14): 3768-79. [Abstract] [Full-text]
4. Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models.
   J Neuropathol Exp Neurol, 66(4): 313-20. [Abstract] [Full-text]
5. Role of brain-derived neurotrophic factor in Huntington's disease.
   Prog Neurobiol, 81(5): 294-330. [Abstract] [Full-text]
6. Abnormal intracortical facilitation in early-stage Huntington's disease.
   Clin Neurophysiol, 118(5): 1149-54. [Abstract] [Full-text]
7. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
   Neurosci Lett, 417(1): 78-83. [Abstract] [Full-text]
8. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease.
   Prog Neurobiol, 81(5): 331-48. [Abstract] [Full-text]
9. The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases.
   Prog Neurobiol, 81(5): 349-79. [Abstract] [Full-text]
10. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease.
    Prog Neurobiol, 81(5): 272-93. [Abstract] [Full-text]
11. The corticostriatal pathway in Huntington's disease.
    Prog Neurobiol, 81(5): 253-71. [Abstract] [Full-text]
12. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.
    Neurobiol Dis, 26(2): 375-84. [Abstract] [Full-text]
13. Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease.
    J Neurosci, 27(16): 4424-34. [Abstract] [Full-text]
14. The relationship between CAG repeat length and age of onset differs for Huntington's disease patients with juvenile onset or adult onset.
    Ann Hum Genet, 71: 295-301. [Abstract] [Full-text]
15. Motor timing variability increases in preclinical Huntington's disease patients as estimated onset of motor symptoms approaches.
    J Int Neuropsychol Soc, 13(3): 539-43. [Abstract] [Full-text]
16. Attention, inhibition, and proximity to clinical onset in preclinical mutation carriers for Huntington's disease.
    J Clin Exp Neuropsychol, 29(3): 235-46. [Abstract] [Full-text]
17. A common SNP haplotype provides molecular proof of a founder effect of Huntington disease linking two South African populations.
    Eur J Hum Genet, 15(5): 590-5. [Abstract] [Full-text]

© 2005-2008 Huntington's Disease Research Today. All Rights Reserved.